Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug;28(8):373-82.
doi: 10.1093/intimm/dxw021. Epub 2016 Apr 27.

Rational Bases for the Use of the Immunoscore in Routine Clinical Settings as a Prognostic and Predictive Biomarker in Cancer Patients

Free PMC article

Rational Bases for the Use of the Immunoscore in Routine Clinical Settings as a Prognostic and Predictive Biomarker in Cancer Patients

Amos Kirilovsky et al. Int Immunol. .
Free PMC article


The American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) tumor, nodes, metastasis (TNM) classification system based on tumor features is used for prognosis estimation and treatment recommendations in most cancers. However, the clinical outcome can vary significantly among patients within the same tumor stage and TNM classification does not predict response to therapy. Therefore, many efforts have been focused on the identification of new markers. Multiple tumor cell-based approaches have been proposed but very few have been translated into the clinic. The recent demonstration of the essential role of the immune system in tumor progression has allowed great advances in the understanding of this complex disease and in the design of novel therapies. The analysis of the immune infiltrate by imaging techniques in large patient cohorts highlighted the prognostic impact of the in situ immune cell infiltrate in tumors. Moreover, the characterization of the immune infiltrates (e.g. type, density, distribution within the tumor, phenotype, activation status) in patients treated with checkpoint-blockade strategies could provide information to predict the disease outcome. In colorectal cancer, we have developed a prognostic score ('Immunoscore') that takes into account the distribution of the density of both CD3(+) lymphocytes and CD8(+) cytotoxic T cells in the tumor core and the invasive margin that could outperform TNM staging. Currently, an international retrospective study is under way to validate the Immunoscore prognostic performance in patients with colon cancer. The use of Immunoscore in clinical practice could improve the patients' prognostic assessment and therapeutic management.

Keywords: T cells; colorectal cancer; immune response; lymphocyte; tumor microenvironment.


Fig. 1.
Fig. 1.
(A) A section of colonic cancer immunostained for CD3, showing the regions of interest (the CT and the IM). (B) An enlargement showing CD3+ cells (stained brown) in the stroma and within tumor glands (original magnification ×300). (C) The tumor (shown in red) and the IM (shown in brown) are selected to determine the Immunoscore. (D) The Immunoscore is based on the numeration of CD3+ and of CD8+ cells in the tumor and the IM. The densities of stained cells are determined using an image analysis workstation. The immune densities are categorized into Hi (high) or Lo (low) in each tumor region, according to a predetermined cutoff value. Patients are stratified according to a score ranging from I0 to I4, depending on the total number of high densities observed (the two markers CD3 and CD8 are assessed in the CT and the two markers are assessed in the IM).

Similar articles

  • Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.
    Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pagès F. Galon J, et al. J Pathol. 2014 Jan;232(2):199-209. doi: 10.1002/path.4287. J Pathol. 2014. PMID: 24122236 Free PMC article. Review.
  • Prognostic and predictive values of immune infiltrate in patients with head and neck squamous cell carcinoma.
    Zhang XM, Song LJ, Shen J, Yue H, Han YQ, Yang CL, Liu SY, Deng JW, Jiang Y, Fu GH, Shen WW. Zhang XM, et al. Hum Pathol. 2018 Dec;82:104-112. doi: 10.1016/j.humpath.2018.07.012. Epub 2018 Jul 20. Hum Pathol. 2018. PMID: 30036594
  • Application of the Immunoscore as prognostic tool for hepatocellular carcinoma.
    Petrizzo A, Buonaguro L. Petrizzo A, et al. J Immunother Cancer. 2016 Nov 15;4:71. doi: 10.1186/s40425-016-0182-5. eCollection 2016. J Immunother Cancer. 2016. PMID: 27879973 Free PMC article.
  • International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.
    Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Mușină AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J. Pagès F, et al. Lancet. 2018 May 26;391(10135):2128-2139. doi: 10.1016/S0140-6736(18)30789-X. Epub 2018 May 10. Lancet. 2018. PMID: 29754777
  • Cancer classification using the Immunoscore: a worldwide task force.
    Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Galon J, et al. J Transl Med. 2012 Oct 3;10:205. doi: 10.1186/1479-5876-10-205. J Transl Med. 2012. PMID: 23034130 Free PMC article. Review.
See all similar articles

Cited by 43 articles

See all "Cited by" articles

Publication types